BibTex RIS Kaynak Göster

Evaluation of the Kidney Disease Developed Malignancy Patients

Yıl 2018, Cilt: 4 Sayı: 2, 90 - 96, 01.04.2018
https://doi.org/10.5455/umj.20180323033247

Öz

Background: Renal involvement in malignant patients may lead to kidney disease indirectly for a number of reasons, including direct metastasis or dehydration, hyperuricemia, and tumor lysis syndrome. We aimed to evaluate malignant patients who developed kidney disease in our study. Method: This study was performed in malignant patients who applied to the Kahramanmaras Necip Fazil City hospital between 2015-2017. Blood urea nitrogen, serum creatinine, uric acid, sodium, potassium, calcium, phosphorus, glucose, complete urine output and hemogram were noted in patients with kidney disease. Results: A total of 688 cancer patients were included in the study. 53.6% of the patients were female and 46.2% were male. The average age of the patients was found as 60.23±13.25 21-94 . Acute kidney injury was detected in %17,1. When the patients diagnosed with kidney disease were evaluated; serum uric acid levels were higher in 46.2% of patients, calcium-level was low in 7.7% of patients and high in 3.6% of patients, serum potassium level was high in 21.1% of patients, phosphorus level was high in 42.9% and serum sodium level was low in 17.2% of patients. According to Kidney Disease Improve Global Outcomes, the acute renal injury was detected in 42.4% of stage-I, 25.4% of stage II, and 32.2% of stage-III. 33 of 118 patients with acute renal injury died. Conclusion: In our study, the incidence of acute renal injury was 17.1% in the cancer patients. The mortality rate was higher in the patients with the acute renal injury.

Kaynakça

  • WHO. What1. Olabisi O and Bonventre JV. Acute Kidney Injury in Cancer Patients. Onconephrology. 2015;1-25.
  • Schrier RW. Cancer therapy and renal injury. The Journal of Clinical Investigation 2002;10(6):743–745.
  • Gallieni M, Cosmai L, Porta C. Acute Kidney Injury in Cancer Patients. Contrib Nephrol. Basel. Karger, 2018;193:137–148.
  • Edeani A and Shirali A. Tumor Lysis Syndrome. American Society of Nephrology, 2016.
  • Launay-Vacher V, Izzedine H, Rey JB, Rixe O, Chapalain S, Nourdine S, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004;10:CR209–CR212.
  • Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84.
  • Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815-21.
  • Dogan E, Izmirli M, Ceylan K, Erkoc R, Sayarlioglu H, Begenik H, et al. Incidence of renal insufficiency in cancer patients. Adv Ther. 2005;22:357–362.
  • Kapoor M, Chan GZ. Malignancy and renal disease. Crit Care Clin. 2001;17:571-598.
  • Lameire NH, Flombaum C, Moreau D, Ronco C. Acute renal failure in cancer patients. Annals of Medicine. 2005;37:13-25.
  • Gallieni M, Cosmai L, Porta C. Acute Kidney Injury in Cancer Patients. Contrib Nephrol. Basel, Karger. 2018;193:137–148.
  • Rosner MH, Dalkin AC. Onco-nephrology: pathophysiology and treatment of malignancy- associated hypercalcemia. Clin J Am Soc Nephrol. 2012; 7: 1722–1729.
  • Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicaseera. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco- Hematologique. Br J Haematol. 2013;162(4):489–97.
  • Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. Contrib Nephrol. 2005;147:47–60.
  • Spencer HW, Yarger WE, Robinson RR. Alterations of renal function during dietary-induced hyperuricemia in therat. Kidney Int. 1976;9(6):489–500.
  • Yao KH, Touré M, Coulibaly N, Diopoh SP, Konan SD, Kouassi Y, et al. Renal failure in cancer patients: results from the national cancer registry of Abidjan, Côted'Ivoire. Journal of Nephropathology. 2017;6(4).
Yıl 2018, Cilt: 4 Sayı: 2, 90 - 96, 01.04.2018
https://doi.org/10.5455/umj.20180323033247

Öz

Kaynakça

  • WHO. What1. Olabisi O and Bonventre JV. Acute Kidney Injury in Cancer Patients. Onconephrology. 2015;1-25.
  • Schrier RW. Cancer therapy and renal injury. The Journal of Clinical Investigation 2002;10(6):743–745.
  • Gallieni M, Cosmai L, Porta C. Acute Kidney Injury in Cancer Patients. Contrib Nephrol. Basel. Karger, 2018;193:137–148.
  • Edeani A and Shirali A. Tumor Lysis Syndrome. American Society of Nephrology, 2016.
  • Launay-Vacher V, Izzedine H, Rey JB, Rixe O, Chapalain S, Nourdine S, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004;10:CR209–CR212.
  • Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376-84.
  • Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815-21.
  • Dogan E, Izmirli M, Ceylan K, Erkoc R, Sayarlioglu H, Begenik H, et al. Incidence of renal insufficiency in cancer patients. Adv Ther. 2005;22:357–362.
  • Kapoor M, Chan GZ. Malignancy and renal disease. Crit Care Clin. 2001;17:571-598.
  • Lameire NH, Flombaum C, Moreau D, Ronco C. Acute renal failure in cancer patients. Annals of Medicine. 2005;37:13-25.
  • Gallieni M, Cosmai L, Porta C. Acute Kidney Injury in Cancer Patients. Contrib Nephrol. Basel, Karger. 2018;193:137–148.
  • Rosner MH, Dalkin AC. Onco-nephrology: pathophysiology and treatment of malignancy- associated hypercalcemia. Clin J Am Soc Nephrol. 2012; 7: 1722–1729.
  • Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicaseera. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco- Hematologique. Br J Haematol. 2013;162(4):489–97.
  • Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. Contrib Nephrol. 2005;147:47–60.
  • Spencer HW, Yarger WE, Robinson RR. Alterations of renal function during dietary-induced hyperuricemia in therat. Kidney Int. 1976;9(6):489–500.
  • Yao KH, Touré M, Coulibaly N, Diopoh SP, Konan SD, Kouassi Y, et al. Renal failure in cancer patients: results from the national cancer registry of Abidjan, Côted'Ivoire. Journal of Nephropathology. 2017;6(4).
Toplam 16 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Research Article
Yazarlar

Can Huzmeli

Yayımlanma Tarihi 1 Nisan 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 4 Sayı: 2

Kaynak Göster

Vancouver Huzmeli C. Evaluation of the Kidney Disease Developed Malignancy Patients. ULUTAS MED J. 2018;4(2):90-6.